Cargando…
Neprilysin Is Required for Angiotensin-(1–7)’s Ability to Enhance Insulin Secretion via Its Proteolytic Activity to Generate Angiotensin-(1–2)
Recent work has renewed interest in therapies targeting the renin-angiotensin system (RAS) to improve β-cell function in type 2 diabetes. Studies show that generation of angiotensin-(1–7) by ACE2 and its binding to the Mas receptor (MasR) improves glucose homeostasis, partly by enhancing glucose-sti...
Autores principales: | Brar, Gurkirat S., Barrow, Breanne M., Watson, Matthew, Griesbach, Ryan, Choung, Edwina, Welch, Andrew, Ruzsicska, Bela, Raleigh, Daniel P., Zraika, Sakeneh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521860/ https://www.ncbi.nlm.nih.gov/pubmed/28559246 http://dx.doi.org/10.2337/db16-1318 |
Ejemplares similares
-
Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022) -
Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx
por: Zraika, Sakeneh, et al.
Publicado: (2013) -
A Mouse Model of Beta-Cell Dysfunction as Seen in Human Type 2 Diabetes
por: Parilla, Jacqueline H., et al.
Publicado: (2018) -
Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021) -
Angiotensin I–Converting Enzyme Type 2 (ACE2) Gene Therapy Improves Glycemic Control in Diabetic Mice
por: Bindom, Sharell M., et al.
Publicado: (2010)